Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility
Open Access
- 1 August 2005
- journal article
- research article
- Published by Elsevier in Laboratory Investigation
- Vol. 18 (8) , 1015-1021
- https://doi.org/10.1038/modpathol.3800432
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Comparative Assays for the HER-2/neu Oncogene Status in Breast CancerArchives of Pathology & Laboratory Medicine, 2004
- Emerging Technologies for HER2 TestingOncology, 2002
- Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast CancerJournal of Clinical Oncology, 2002
- The HER‐2/ neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for TherapyThe International Journal of Cell Cloning, 1998
- The prognostic value of c-erbB2 in primary breast carcinomas: A study on 942 casesBreast Cancer Research and Treatment, 1995
- Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatmentGene, 1995
- Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.Journal of Clinical Oncology, 1995
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12–21.32Genomics, 1989
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987